Ipratropium vs Umeclidinium

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline

Ipratropium

Marketed by Boehringer Ingelheim

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Umeclidinium · Incruse Ellipta

Marketed by GlaxoSmithKline

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule
Reliable signal

NCT02184611 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial in 308 patients using lung function (trough FEV1) as its primary measure, and umeclidinium produced a significantly greater improvement than placebo (least-squares mean difference 0.154 L, 95% CI 0.113 to 0.194, p<0.001).

Reported efficacy

Change From Baseline in Trough (Pre-bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) on Treatment Day 169 (Baseline (Day 1) and Day 169): Change from baseline in trough FEV1 at Day 169 (primary endpoint): UMEC 62.5 mcg vs placebo, LS mean treatment difference 154 mL (95% CI 113, 194; p<0.001) (met)

Result source: NCT02184611

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIpratropiumUmeclidinium
Moderate or severe exacerbations, annualised rate—Not posted · NCT02177344—Trial running · NCT06474039
Trough FEV1, change—Not posted · NCT021773440.1 vs -0.0+0.2 vs placebo62.5 mcg · wk 24 · n 176NCT02184611
21 other results
  • 0.1 vs -0.0 62.5 µg · wk 12.14 · n 195 · Phase 3 · primary NCT01957163
  • 0.1 vs -0.0 125 µg QD · wk 12.14 · n 183 · Phase 3 · primary NCT01772147
  • 0.1 vs -0.0 125 µg · wk 12.14 · n 188 · Phase 3 · primary NCT01957163
  • 0.1 vs -0.0 125 µg QD · wk 12 · n 184 · Phase 3 · primary NCT01772134
  • 0.1 vs -0.0 62.5 µg QD · wk 12.14 · n 178 · Phase 3 · primary NCT01772147
  • 0.1 vs -0.0 62.5 µg QD · wk 12 · n 190 · Phase 3 · primary NCT01772134
  • 0.1 vs -0.0 125 µg · wk 12.14 · n 199 · Phase 3 · primary NCT02119286
  • 0.1 vs -0.0 62.5 µg · wk 12.14 · n 195 · Phase 3 · primary NCT02119286
  • 0.2 vs 0.1 62.5 mcg QD · wk 12.14 · n 392 · Phase 3 · primary NCT02207829
  • 0.2 vs 0.2 62.5/25 µg · wk 12.14 · n 392 · Phase 3 · primary NCT02257385
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.2 vs 0.0 62.5/25 mcg · wk 12 · n 227 · Phase 3 · secondary NCT02152605
  • 0.2 vs 0.1 62.5/25 mcg · wk 12.14 · n 349 · Phase 3 · secondary NCT01879410
  • 0.1 vs -0.0 62.5 mcg+ICS/LABA · wk 12 · n 109 · Phase 4 · primary NCT02257372
  • 0.1 vs -0.0 62.5/25 mcg · wk 24 · n 691 · Phase 4 · primary NCT03034915
  • 0.1 vs 0.1 62.5 mcg QD · wk 12 · n 431 · Phase 4 · primary NCT02236611
  • 0.1 vs 0.1 100/250 µg · wk 4 · n 81 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/125 µg · wk 4 · n 44 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.1 100/15.6 µg · wk 4 · n 42 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/62.5 µg · wk 4 · n 39 · Phase 2 · primary NCT02164539
  • 0.2 vs -0.0 62.5/25 mcg · wk 12 · n 175 · Phase 4 · secondary NCT02275052
SGRQ total, change—Not posted · NCT02177344-6.2 vs -2.1−4 vs placebo62.5/25 mcg · wk 12 · n 212NCT02152605
5 other results
  • -7.3 vs -4.3 62.5 mcg · wk 24 · n 205 · Phase 3 · secondary NCT02184611
  • -7.0 vs -2.5 62.5 mcg · wk 12 · n 205 · Phase 3 · secondary NCT02184611
  • -5.8 vs -1.4 62.5 mcg · wk 4 · n 205 · Phase 3 · secondary NCT02184611
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051
  • -5.0 vs -3.3 62.5/25 mcg · wk 24 · n 704 · Phase 4 · secondary NCT03034915
TDI focal score—Not posted · NCT021773442.5 vs 1.6+0.9 vs placebo62.5 mcg · wk 24 · n 176NCT02184611

Moderate or severe exacerbations, annualised rate

Ipratropium
—Not posted · NCT02177344
Umeclidinium
—Trial running · NCT06474039

Trough FEV1, change

Ipratropium
—Not posted · NCT02177344
Umeclidinium
0.1 vs -0.0+0.2 vs placebo62.5 mcg · wk 24 · n 176NCT02184611
21 other results
  • 0.1 vs -0.0 62.5 µg · wk 12.14 · n 195 · Phase 3 · primary NCT01957163
  • 0.1 vs -0.0 125 µg QD · wk 12.14 · n 183 · Phase 3 · primary NCT01772147
  • 0.1 vs -0.0 125 µg · wk 12.14 · n 188 · Phase 3 · primary NCT01957163
  • 0.1 vs -0.0 125 µg QD · wk 12 · n 184 · Phase 3 · primary NCT01772134
  • 0.1 vs -0.0 62.5 µg QD · wk 12.14 · n 178 · Phase 3 · primary NCT01772147
  • 0.1 vs -0.0 62.5 µg QD · wk 12 · n 190 · Phase 3 · primary NCT01772134
  • 0.1 vs -0.0 125 µg · wk 12.14 · n 199 · Phase 3 · primary NCT02119286
  • 0.1 vs -0.0 62.5 µg · wk 12.14 · n 195 · Phase 3 · primary NCT02119286
  • 0.2 vs 0.1 62.5 mcg QD · wk 12.14 · n 392 · Phase 3 · primary NCT02207829
  • 0.2 vs 0.2 62.5/25 µg · wk 12.14 · n 392 · Phase 3 · primary NCT02257385
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.2 vs 0.0 62.5/25 mcg · wk 12 · n 227 · Phase 3 · secondary NCT02152605
  • 0.2 vs 0.1 62.5/25 mcg · wk 12.14 · n 349 · Phase 3 · secondary NCT01879410
  • 0.1 vs -0.0 62.5 mcg+ICS/LABA · wk 12 · n 109 · Phase 4 · primary NCT02257372
  • 0.1 vs -0.0 62.5/25 mcg · wk 24 · n 691 · Phase 4 · primary NCT03034915
  • 0.1 vs 0.1 62.5 mcg QD · wk 12 · n 431 · Phase 4 · primary NCT02236611
  • 0.1 vs 0.1 100/250 µg · wk 4 · n 81 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/125 µg · wk 4 · n 44 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.1 100/15.6 µg · wk 4 · n 42 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/62.5 µg · wk 4 · n 39 · Phase 2 · primary NCT02164539
  • 0.2 vs -0.0 62.5/25 mcg · wk 12 · n 175 · Phase 4 · secondary NCT02275052

SGRQ total, change

Ipratropium
—Not posted · NCT02177344
Umeclidinium
-6.2 vs -2.1−4 vs placebo62.5/25 mcg · wk 12 · n 212NCT02152605
5 other results
  • -7.3 vs -4.3 62.5 mcg · wk 24 · n 205 · Phase 3 · secondary NCT02184611
  • -7.0 vs -2.5 62.5 mcg · wk 12 · n 205 · Phase 3 · secondary NCT02184611
  • -5.8 vs -1.4 62.5 mcg · wk 4 · n 205 · Phase 3 · secondary NCT02184611
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051
  • -5.0 vs -3.3 62.5/25 mcg · wk 24 · n 704 · Phase 4 · secondary NCT03034915

TDI focal score

Ipratropium
—Not posted · NCT02177344
Umeclidinium
2.5 vs 1.6+0.9 vs placebo62.5 mcg · wk 24 · n 176NCT02184611
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Ipratropium: registry results are on file for Chronic Obstructive Pulmonary Disease, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Ipratropium: 0 of 4 rows · Umeclidinium: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricUmeclidinium
Dropout rate
13.7%62.5 mcga
NCT02184611 · Phase 3
show 25 more results
8.9%125 µg QD
NCT01772147 · Phase 3 · combination
12.3%62.5 µg QD
NCT01772147 · Phase 3 · combination
5.3%62.5 µg
NCT01957163 · Phase 3 · combination
8.7%125 µg
NCT01957163 · Phase 3 · combination
3.4%125 µg
NCT02119286 · Phase 3 · combination
5.3%62.5 µg
NCT02119286 · Phase 3 · combination
10.7%125 µg QD
NCT01772134 · Phase 3 · combination
6.9%62.5 µg QD
NCT01772134 · Phase 3 · combination
11.7%62.5/25 mcg
NCT03034915 · Phase 4 · registry result, not featured evidence
—62.5/25 mcg
NCT02275052 · Phase 4 · registry result, not featured evidence
5%62.5 mcg QD
NCT02236611 · Phase 4 · registry result, not featured evidence
8.4%62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
5.7%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
8.3%62.5 mcg QD
NCT02207829 · Phase 3 · registry result, not featured evidence
4.6%62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
7.3%62.5/25 mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
—62.5/25mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
—62.5/25 mcg
NCT01879410 · Phase 3 · registry result, not featured evidence
—62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
—62.5/25 µg once daily
NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
3.5%100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
4.3%100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
2.5%100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
2.4%62.5 mcga
NCT02184611 · Phase 3
show 25 more results
3%125 µg QD
NCT01772147 · Phase 3 · combination
4.9%62.5 µg QD
NCT01772147 · Phase 3 · combination
1%62.5 µg
NCT01957163 · Phase 3 · combination
1.9%125 µg
NCT01957163 · Phase 3 · combination
1%125 µg
NCT02119286 · Phase 3 · combination
3.4%62.5 µg
NCT02119286 · Phase 3 · combination
4.9%125 µg QD
NCT01772134 · Phase 3 · combination
2.5%62.5 µg QD
NCT01772134 · Phase 3 · combination
3.6%62.5/25 mcg
NCT03034915 · Phase 4 · registry result, not featured evidence
—62.5/25 mcg
NCT02275052 · Phase 4 · registry result, not featured evidence
1.9%62.5 mcg QD
NCT02236611 · Phase 4 · registry result, not featured evidence
5.9%62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
2%62.5 mcg QD
NCT02207829 · Phase 3 · registry result, not featured evidence
2.5%62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
3.2%62.5/25 mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
—62.5/25mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
—62.5/25 mcg
NCT01879410 · Phase 3 · registry result, not featured evidence
—62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
—62.5/25 µg once daily
NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
—100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
8.3%62.5 mcga
NCT02184611 · Phase 3
show 25 more results
3%125 µg QD
NCT01772147 · Phase 3 · combination
3%62.5 µg QD
NCT01772147 · Phase 3 · combination
1%62.5 µg
NCT01957163 · Phase 3 · combination
3.4%125 µg
NCT01957163 · Phase 3 · combination
1.4%125 µg
NCT02119286 · Phase 3 · combination
3.9%62.5 µg
NCT02119286 · Phase 3 · combination
2.9%125 µg QD
NCT01772134 · Phase 3 · combination
2%62.5 µg QD
NCT01772134 · Phase 3 · combination
6%62.5/25 mcg
NCT03034915 · Phase 4 · registry result, not featured evidence
3%62.5/25 mcg
NCT02275052 · Phase 4 · registry result, not featured evidence
3.3%62.5 mcg QD
NCT02236611 · Phase 4 · registry result, not featured evidence
5%62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
10.4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
3.3%62.5 mcg QD
NCT02207829 · Phase 3 · registry result, not featured evidence
4.4%62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
—62.5/25 mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
6.9%62.5/25mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
3.2%62.5/25 mcg
NCT01879410 · Phase 3 · registry result, not featured evidence
0.5%62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
1.7%62.5/25 µg once daily
NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
0.5%100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
62.5 mcga
upper respiratory tract infection 12.2% (placebo 12.9%)
nasopharyngitis 9.3% (placebo 10.9%)
dizziness 2.9% (placebo 2%)
NCT02184611 · Phase 3
show 23 more results
125 µg QD
nasopharyngitis 5% (placebo 4.5%)
headache 3% (placebo 4.5%)
NCT01772147 · Phase 3 · combination
62.5 µg QD
headache 4.4% (placebo 4.5%)
nasopharyngitis 3% (placebo 4.5%)
NCT01772147 · Phase 3 · combination
62.5 µg
headache 4.4% (placebo 2.9%)
back pain 3.4% (placebo 1.5%)
nasopharyngitis 3.4% (placebo 3.4%)
NCT01957163 · Phase 3 · combination
125 µg
nasopharyngitis 4.8% (placebo 3.4%)
headache 4.3% (placebo 2.9%)
cough 3.4% (placebo 0.5%)
NCT01957163 · Phase 3 · combination
125 µg
nasopharyngitis 9.2% (placebo 10.7%)
headache 1.9% (placebo 2.4%)
back pain 1% (placebo 1.9%)
NCT02119286 · Phase 3 · combination
62.5 µg
nasopharyngitis 5.3% (placebo 10.7%)
back pain 3.9% (placebo 1.9%)
headache 3.9% (placebo 2.4%)
NCT02119286 · Phase 3 · combination
125 µg QD
headache 6.3% (placebo 4.9%)
cough 2.4% (placebo 1.5%)
nasopharyngitis 2.4% (placebo 4.9%)
NCT01772134 · Phase 3 · combination
62.5 µg QD
headache 4.4% (placebo 4.9%)
cough 3.4% (placebo 1.5%)
nasopharyngitis 2.5% (placebo 4.9%)
NCT01772134 · Phase 3 · combination
62.5/25 mcg
nasopharyngitis 8.4%
NCT03034915 · Phase 4 · registry result, not featured evidence
62.5 mcg QD
headache 8.1%
nasopharyngitis 8.1%
NCT02236611 · Phase 4 · registry result, not featured evidence
62.5 mcg+ICS/LABA
nasopharyngitis 13.4% (placebo 14.5%)
headache 3.4% (placebo 6.8%)
cough 2.5% (placebo 4.3%)
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
100/62.5/25
viral upper respiratory tract infection 10.6%
headache 6.1%
upper respiratory tract infection 3.4%
NCT02729051 · Phase 3 · registry result, not featured evidence
62.5 mcg QD
headache 5.9%
nasopharyngitis 5.3%
NCT02207829 · Phase 3 · registry result, not featured evidence
62.5/25 µg
headache 7.5%
nasopharyngitis 6.6%
cough 3.3%
NCT02257385 · Phase 3 · registry result, not featured evidence
62.5/25mcg
headache 6.5% (placebo 6.5%)
nasopharyngitis 5.2% (placebo 6.5%)
NCT02152605 · Phase 3 · registry result, not featured evidence
62.5/25 mcg
headache 6.9%
nasopharyngitis 4%
NCT01879410 · Phase 3 · registry result, not featured evidence
62.5/25 µg
headache 5%
NCT02014480 · Phase 3 · registry result, not featured evidence
62.5/25 µg once daily
nasopharyngitis 4%
headache 3.5%
NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
100/250 µg
nasopharyngitis 1.9%
toothache 0.5%
dysphonia 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/125 µg
dysphonia 6.5%
nasopharyngitis 4.3%
toothache 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/15.6 µg
nasopharyngitis 7.1%
toothache 7.1%
dysphonia 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/62.5 µg
nasopharyngitis 5%
dysphonia 2.5%
toothache 2.5%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/250/25 µg
dysphonia 0%
nasopharyngitis 0%
toothache 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 25 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Umeclidinium

FEV1 Trough 0.131 vs -0.022 placebo L @ 24wk62.5 mcg
absolute change · L
NCT02184611 · Phase 3
show 21 more results
0.103 vs -0.02 placebo L @ 12.14wk62.5 µg
NCT01957163 · Phase 3 · combination
0.122 vs 0.056 UMEC L @ 24wk62.5/25 mcg
NCT03034915 · Phase 4 · registry result, not featured evidence
0.173 vs -0.034 placebo L @ 12wk62.5/25 mcg
NCT02275052 · Phase 4 · registry result, not featured evidence
0.123 vs 0.099 GLYCO L @ 12wk62.5 mcg QD
NCT02236611 · Phase 4 · registry result, not featured evidence
0.09 vs -0.033 placebo L @ 12wk62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
0.154 vs 0.095 Tiotropium L @ 12.14wk62.5 mcg QD
NCT02207829 · Phase 3 · registry result, not featured evidence
0.172 vs 0.171 Indacaterol + Tiotropium Bromide L @ 12.14wk62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
0.152 vs 0.03 placebo L @ 12wk62.5/25 mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
0.185 vs 0.087 FSC L @ 12.14wk62.5/25 mcg
NCT01879410 · Phase 3 · registry result, not featured evidence
0.147 vs -0.001 placebo L @ 12.14wk125 µg QD
NCT01772147 · Phase 3 · combination
0.108 vs -0.02 placebo L @ 12.14wk125 µg
NCT01957163 · Phase 3 · combination
0.116 vs -0.022 placebo L @ 12wk125 µg QD
NCT01772134 · Phase 3 · combination
0.126 vs -0.001 placebo L @ 12.14wk62.5 µg QD
NCT01772147 · Phase 3 · combination
0.125 vs -0.022 placebo L @ 12wk62.5 µg QD
NCT01772134 · Phase 3 · combination
0.143 vs 0.047 FF L @ 4wk100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.081 vs -0.03 placebo L @ 12.14wk125 µg
NCT02119286 · Phase 3 · combination
0.175 vs 0.047 FF L @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.146 vs 0.047 FF L @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.193 vs 0.047 FF L @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.092 vs -0.03 placebo L @ 12.14wk62.5 µg
NCT02119286 · Phase 3 · combination
0.113 vs 0.095 FF/VI + UMEC L @ 24wk100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
TDI Focal 2.5 vs 1.6 placebo score @ 24wk62.5 mcg
absolute change · score
NCT02184611 · Phase 3
FEV1 Wm0 6 h 0.136 vs 0.011 placebo L @ 0wk62.5 mcg
absolute change · L
NCT02184611 · Phase 3
show 10 more results
0.187 vs 0.034 placebo L @ 12wk62.5 µg
NCT01957163 · Phase 3 · combination
0.184 vs 0.035 placebo L @ 12wk62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
0.235 vs 0.258 Indacaterol + Tiotropium Bromide L @ 12wk62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
0.217 vs 0.052 placebo L @ 12wk125 µg QD
NCT01772147 · Phase 3 · combination
0.175 vs 0.034 placebo L @ 12wk125 µg
NCT01957163 · Phase 3 · combination
0.192 vs 0.032 placebo L @ 12wk125 µg QD
NCT01772134 · Phase 3 · combination
0.196 vs 0.052 placebo L @ 12wk62.5 µg QD
NCT01772147 · Phase 3 · combination
0.196 vs 0.032 placebo L @ 12wk62.5 µg QD
NCT01772134 · Phase 3 · combination
0.152 vs 0.017 placebo L @ 12wk125 µg
NCT02119286 · Phase 3 · combination
0.164 vs 0.017 placebo L @ 12wk62.5 µg
NCT02119286 · Phase 3 · combination
SGRQ Total -5.84 vs -1.45 placebo score @ 4wk62.5 mcg
absolute change · score
NCT02184611 · Phase 3
show 5 more results
-7.05 vs -2.46 placebo score @ 12wk62.5 mcg
NCT02184611 · Phase 3
-7.34 vs -4.31 placebo score @ 24wk62.5 mcg
NCT02184611 · Phase 3
-4.98 vs -5.23 UMEC score @ 24wk62.5/25 mcg
NCT03034915 · Phase 4 · registry result, not featured evidence
-6.15 vs -2.12 placebo score @ 12wk62.5/25 mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
-5.841 vs -4.935 FF/VI + UMEC score @ 24wk100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
CAT Total -1.75 vs -0.26 placebo score @ 4wk62.5 mcg
absolute change · score
NCT02184611 · Phase 3
show 2 more results
-2.18 vs -0.08 placebo score @ 12wk62.5 mcg
NCT02184611 · Phase 3
-2 vs -1.32 placebo score @ 24wk62.5 mcg
NCT02184611 · Phase 3
Rescue-free 24-h Period 15.2 vs 1.9 placebo % of time @ 12wk125 µg QD
percent change · % of time
NCT01772147 · Phase 3 · combination
show 1 more result
8.4 vs 1.9 placebo % of time @ 12wk62.5 µg QD
NCT01772147 · Phase 3 · combination
Rescue Puffs -0.7 vs -0.2 placebo puffs @ 12wk125 µg QD
absolute change · puffs
NCT01772147 · Phase 3 · combination
show 3 more results
-0.5 vs -0.2 placebo puffs @ 12wk125 µg QD
NCT01772134 · Phase 3 · combination
-0.4 vs -0.2 placebo puffs @ 12wk62.5 µg QD
NCT01772147 · Phase 3 · combination
-0.5 vs -0.2 placebo puffs @ 12wk62.5 µg QD
NCT01772134 · Phase 3 · combination
Rescue-free 24 h Periods 11.1 vs 4.9 placebo % of time @ 12wk125 µg QD
absolute change · % of time
NCT01772134 · Phase 3 · combination
show 1 more result
13.3 vs 4.9 placebo % of time @ 12wk62.5 µg QD
NCT01772134 · Phase 3 · combination
TDI Focal 1.68 vs 1.3 UMEC score @ 24wk62.5/25 mcg
absolute value · score
NCT03034915 · Phase 4 · registry result, not featured evidence
TDI Focal 50% (n=806) vs 42% (n=799) UMEC @ 24wk62.5/25 mcg
responder rate · % of participants
NCT03034915 · Phase 4 · registry result, not featured evidence
show 1 more result
56% (n=482) vs 56% (n=481) FF/VI + UMEC @ 24wk100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
E-RS Total -1.52 vs -0.99 UMEC score @ 24wk62.5/25 mcg
absolute change · score
NCT03034915 · Phase 4 · registry result, not featured evidence
show 4 more results
-1.5 vs 0.5 FF score @ 4wk100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-1.5 vs 0.5 FF score @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-2.6 vs 0.5 FF score @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-2.5 vs 0.5 FF score @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
E-RS Cough Sputum Domain -0.45 vs -0.38 UMEC score @ 24wk62.5/25 mcg
absolute change · score
RS-CSP
NCT03034915 · Phase 4 · registry result, not featured evidence

+ 15 further endpoints in the CSV export.

Asthma

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline

Ipratropium

Marketed by Boehringer Ingelheim

Phase 3 in Asthmasmall molecule
Weak signal

NCT06074185 · Phase 2 · completed

The study was not randomized or blinded and compared patients treated before and after implementation of the bundle rather than using a concurrent controlled trial; the intervention also included dexamethasone and a checklist, so the effect cannot be attributed to ipratropium alone. Although hospital admission is a clinical endpoint, the primary comparison was based on a small and internally inconsistent set of reported participants, with no reported significance analysis, so the result is unclear.

No aligned efficacy figure on record for this race.

Umeclidinium · Incruse Ellipta

Marketed by GlaxoSmithKline

Phase 2 in Asthmasmall molecule
Partial signal

NCT01573624 · Phase 2 · completed

The study randomized 421 participants to three 14-day treatment periods and kept participants and investigators blinded, with active comparator arms. Its primary outcomes were lung-function measures rather than hard clinical outcomes, and the results were mixed: trough FEV1 was significantly higher with the 125- and 250-mcg UMEC doses but not with the lower doses.

Reported efficacy

Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period); Percentage of Chance That FF 100 mcg Alone Corrected Change From Baseline FEV1 Response Would Exceed a Target Response by Dose of UMEC Combined With FF 100 mcg (Baseline (Day 1) and Day 15 of each treatment period); Mean Change From Baseline in Trough FEV1 on Day 15 of Each of the 3 Treatment Periods (Baseline (Day 1) and Day 15 of each treatment period): Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period): FF 100 mcg + UMEC 15.6 mcg 0.026 Litres (L) (95% CI -0.0098 to 0.0611) | FF 100 mcg + UMEC 31.25 mcg 0.032 Litres (L) (95% CI -0.0036 to 0.0679) | FF 100 mcg + UMEC 62.5 mcg 0.0385 Litres (L) (95% CI -0.0011 to 0.0745) | FF 100 mcg + UMEC 125 mcg 0.0444 Litres (L) (95% CI 0.0067 to 0.0813) | FF 100 mcg + UMEC 250 mcg 0.051 Litres (L) (95% CI 0.0139 to 0.0873) (mixed)

Result source: NCT01573624

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointIpratropiumUmeclidinium
Severe exacerbations, annualised rate—Not reported—Trial running · NCT04651777
Trough FEV1, change—Not reported0.3 vs 0.1+0.2 vs placebo31.25 mcg QD · wk 24 · n 136NCT03012061
17 other results
  • 0.1 vs 0.0 31.25 µg QD · wk 2 · n 124 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 31.25 µg BID · wk 2 · n 118 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 250 µg QD · wk 2 · n 117 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 125 µg QD · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.3 vs 0.1 62.5 mcg QD · wk 24 · n 139 · Phase 2 · primary NCT03012061
  • 0.1 vs 0.0 62.5 µg QD · wk 2 · n 122 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg QD · wk 2 · n 120 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg BID · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.1 100/250 µg · wk 4 · n 81 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.2 100 mcg + 15.6 mcg · wk 2 · n 154 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 31.25 mcg · wk 2 · n 146 · Phase 2 · primary NCT01573624
  • 0.1 vs 0.2 100 mcg + 62.5 mcg · wk 2 · n 150 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 125 mcg · wk 2 · n 155 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 250 mcg · wk 2 · n 150 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.1 100/125 µg · wk 4 · n 44 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.1 100/15.6 µg · wk 4 · n 42 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/62.5 µg · wk 4 · n 39 · Phase 2 · primary NCT02164539
ACQ-5, change—Not reported—Trial running · NCT04651777
OCS dose reduction—Not reported—Trial running · NCT04651777

Severe exacerbations, annualised rate

Ipratropium
—Not reported
Umeclidinium
—Trial running · NCT04651777

Trough FEV1, change

Ipratropium
—Not reported
Umeclidinium
0.3 vs 0.1+0.2 vs placebo31.25 mcg QD · wk 24 · n 136NCT03012061
17 other results
  • 0.1 vs 0.0 31.25 µg QD · wk 2 · n 124 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 31.25 µg BID · wk 2 · n 118 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 250 µg QD · wk 2 · n 117 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 125 µg QD · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.3 vs 0.1 62.5 mcg QD · wk 24 · n 139 · Phase 2 · primary NCT03012061
  • 0.1 vs 0.0 62.5 µg QD · wk 2 · n 122 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg QD · wk 2 · n 120 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg BID · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.1 100/250 µg · wk 4 · n 81 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.2 100 mcg + 15.6 mcg · wk 2 · n 154 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 31.25 mcg · wk 2 · n 146 · Phase 2 · primary NCT01573624
  • 0.1 vs 0.2 100 mcg + 62.5 mcg · wk 2 · n 150 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 125 mcg · wk 2 · n 155 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 250 mcg · wk 2 · n 150 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.1 100/125 µg · wk 4 · n 44 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.1 100/15.6 µg · wk 4 · n 42 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/62.5 µg · wk 4 · n 39 · Phase 2 · primary NCT02164539

ACQ-5, change

Ipratropium
—Not reported
Umeclidinium
—Trial running · NCT04651777

OCS dose reduction

Ipratropium
—Not reported
Umeclidinium
—Trial running · NCT04651777
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Ipratropium: 3 of 4 rows · Umeclidinium: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIpratropiumUmeclidinium
Dropout rate
—a
NCT06074185 · Phase 2 · combination
show 4 more results
0%
NCT04617015 · Phase 1 · registry result, not featured evidence
0%Arg/Arg Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
5.6%Gly/Gly Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
0%
NCT00583778 · Phase na · registry result, not featured evidence · combination
—100 mcg + 125 mcgb
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 19 more results
—100 mcg + 15.6 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
5.9%31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
2%31.25 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
5.1%250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
9.3%125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
—31.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
6.5%31.25 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
5.8%62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
3.5%100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
4.3%100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
2.5%100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—a
NCT06074185 · Phase 2 · combination
show 4 more results
—
NCT04617015 · Phase 1 · registry result, not featured evidence
—Arg/Arg Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
—Gly/Gly Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
—
NCT00583778 · Phase na · registry result, not featured evidence · combination
—100 mcg + 125 mcgb
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 19 more results
—100 mcg + 15.6 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0%31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%31.25 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
—31.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%31.25 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
0%62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
—100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
0%a
NCT06074185 · Phase 2 · combination
show 4 more results
0%
NCT04617015 · Phase 1 · registry result, not featured evidence
0%Arg/Arg Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
0%Gly/Gly Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
0%
NCT00583778 · Phase na · registry result, not featured evidence · combination
0%100 mcg + 125 mcgb
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 19 more results
0%100 mcg + 15.6 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0%100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.6%100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0%100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0%31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
—31.25 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.7%250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%31.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
2.9%31.25 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
2.2%62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
0.5%100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
a
upper respiratory infection 13.3%
dyspnea 6.7%
right foot fracture 6.7%
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
dyspnea 11.8%
cough 5.9%
pneumonia 5.9%
NCT00521222 · Phase na · registry result, not featured evidence
100 mcg + 125 mcgb
headache 2.3%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 18 more results
100 mcg + 15.6 mcg
headache 2.2%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
100 mcg + 250 mcg
headache 3.8%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
100 mcg + 31.25 mcg
headache 1.1%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
100 mcg + 62.5 mcg
headache 2.8%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
31.25 µg BID
headache 4.5% (placebo 1.6%)
nasopharyngitis 1.5% (placebo 0.8%)
pharyngitis 0% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
250 µg QD
headache 4.4% (placebo 1.6%)
product taste abnormal 3.7% (placebo 0%)
nasopharyngitis 0.7% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
125 µg QD
headache 3.1% (placebo 1.6%)
product taste abnormal 3.1% (placebo 0%)
nasopharyngitis 2.3% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
62.5 µg QD
headache 3.8% (placebo 1.6%)
pharyngitis 3.8% (placebo 0.8%)
nasopharyngitis 0.8% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
31.5 µg QD
headache 2.9% (placebo 1.6%)
product taste abnormal 1.4% (placebo 0%)
pharyngitis 0.7% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
15.6 µg BID
nasopharyngitis 3.2% (placebo 0.8%)
headache 1.6% (placebo 1.6%)
pharyngitis 0.8% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
15.6 µg QD
headache 3.8% (placebo 1.6%)
nasopharyngitis 2.3% (placebo 0.8%)
pharyngitis 0% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
31.25 mcg QD
nasopharyngitis 10.1% (placebo 11.9%)
headache 6.5% (placebo 7.7%)
upper respiratory tract infection 5.8% (placebo 2.1%)
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
62.5 mcg QD
nasopharyngitis 9.4% (placebo 11.9%)
headache 8.6% (placebo 7.7%)
upper respiratory tract infection 4.3% (placebo 2.1%)
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
100/250 µg
nasopharyngitis 1.9%
toothache 0.5%
dysphonia 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/125 µg
dysphonia 6.5%
nasopharyngitis 4.3%
toothache 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/15.6 µg
nasopharyngitis 7.1%
toothache 7.1%
dysphonia 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/62.5 µg
nasopharyngitis 5%
dysphonia 2.5%
toothache 2.5%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/250/25 µg
dysphonia 0%
nasopharyngitis 0%
toothache 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 7 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ipratropium

PROMIS Asthma Impact Scale 22.5 score @ 1wk
absolute value · score
No placebo or comparator arm
NCT06074185 · Phase 2 · combination
FEV1 10.8% (n=39)
percent change · % of baseline
No placebo or comparator arm
NCT04617015 · Phase 1 · registry result, not featured evidence
show 1 more result
8.9% (n=32)
NCT04617015 · Phase 1 · registry result, not featured evidence
Morning PEF Change L/Min -15.7 vs -5.6 Fluticasone HFA L/min @ 16wk
absolute change · L/min
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
8.4 vs -5.6 Fluticasone HFA L/min @ 16wk
NCT00521222 · Phase na · registry result, not featured evidence
FEV1 -0.03 vs -0.12 Fluticasone HFA L @ 16wk
absolute change · L
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
-0.08 vs -0.12 Fluticasone HFA L @ 16wk
NCT00521222 · Phase na · registry result, not featured evidence
Post-BD FEV1 Change 0.02 vs -0.11 Fluticasone HFA L @ 16wk
absolute change · L
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
-0.07 vs -0.11 Fluticasone HFA L @ 16wk
NCT00521222 · Phase na · registry result, not featured evidence
FEV1% Predicted -1% (n=15) vs -3.8% (n=13) Fluticasone HFA @ 16wk
absolute change · percentage points
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
-2.5% (n=17) vs -3.8% (n=13) Fluticasone HFA @ 16wk
NCT00521222 · Phase na · registry result, not featured evidence
Asthma Symptom 0.3 vs 0.4 Fluticasone HFA score @ 16wk
absolute change · score
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
-1.2 vs 0.4 Fluticasone HFA score @ 16wk
NCT00521222 · Phase na · registry result, not featured evidence
FEV1 47.5% (n=141) vs 52.5% (n=141) Levalbuterol @ 0wk
responder rate · % of participants
NCT00583778 · Phase na · registry result, not featured evidence · combination · converted to % from 67 Participants as posted
FEV1 Percent Predicted 47% (n=67) vs 45% (n=74) Levalbuterol @ 0wk
absolute change · percentage points
NCT00583778 · Phase na · registry result, not featured evidence · combination

Umeclidinium

FEV1 Trough 0.026 L @ 2wk100 mcg + 15.6 mcg
absolute change · L
No placebo or comparator arm
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 4 more results
0.032 L @ 2wk100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.0385 L @ 2wk100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.0444 L @ 2wk100 mcg + 125 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.051 L @ 2wk100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
FEV1 Trough 0.076 vs 0.046 placebo L @ 2wk31.25 µg QD
absolute change · L
NCT01641692 · Phase 2 · combination · Asthma · phase 2
show 17 more results
0.097 vs 0.046 placebo L @ 2wk31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.3046 vs 0.1289 placebo L @ 24wk31.25 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
0.057 vs 0.046 placebo L @ 2wk250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.143 vs 0.047 FF L @ 4wk100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.134 vs 0.046 placebo L @ 2wk125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.175 vs 0.047 FF L @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.145 vs 0.12 FF L @ 2wk100 mcg + 15.6 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.152 vs 0.12 FF L @ 2wk100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.145 vs 0.12 FF L @ 2wk100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.174 vs 0.12 FF L @ 2wk100 mcg + 125 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.175 vs 0.12 FF L @ 2wk100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.146 vs 0.047 FF L @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.193 vs 0.047 FF L @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.08 vs 0.046 placebo L @ 2wk62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.313 vs 0.1289 placebo L @ 24wk62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
0.112 vs 0.046 placebo L @ 2wk15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.103 vs 0.046 placebo L @ 2wk15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
Morning PEF 13 vs -2.9 FF L100 mcg + 15.6 mcg
absolute change · L
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 4 more results
14.5 vs -2.9 FF L100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
15.7 vs -2.9 FF L100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
20 vs -2.9 FF L100 mcg + 125 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
19 vs -2.9 FF L100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
Evening PEF 11.1 vs -5.2 FF L/min100 mcg + 15.6 mcg
absolute change · L/min
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 4 more results
12.1 vs -5.2 FF L/min100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
16 vs -5.2 FF L/min100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
23.7 vs -5.2 FF L/min100 mcg + 125 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
17.7 vs -5.2 FF L/min100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
FEV1 Wm0 24 h 0.077 vs -0.025 placebo L @ 2wk31.25 µg QD
absolute change · L
NCT01641692 · Phase 2 · combination · Asthma · phase 2
show 6 more results
0.043 vs -0.025 placebo L @ 2wk31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.048 vs -0.025 placebo L @ 2wk250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.094 vs -0.025 placebo L @ 2wk125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.092 vs -0.025 placebo L @ 2wk62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.06 vs -0.025 placebo L @ 2wk15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.097 vs -0.025 placebo L @ 2wk15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
Evening PEF Change L/Min 1.5 vs -5.1 placebo L/min @ 2wk31.25 µg QD
absolute change · L/min
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
show 6 more results
8.7 vs -5.1 placebo L/min @ 2wk31.25 µg BID
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
9.3 vs -5.1 placebo L/min @ 2wk250 µg QD
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
9.8 vs -5.1 placebo L/min @ 2wk125 µg QD
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
-0.9 vs -5.1 placebo L/min @ 2wk62.5 µg QD
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
10 vs -5.1 placebo L/min @ 2wk15.6 µg QD
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
2.5 vs -5.1 placebo L/min @ 2wk15.6 µg BID
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
FEV1 Change 3 h 0.3663 vs 0.1768 placebo L @ 24wk31.25 mcg QD
absolute change · L
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
show 5 more results
0.052 vs 0.048 FF L @ 4wk100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.072 vs 0.048 FF L @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.093 vs 0.048 FF L @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.088 vs 0.048 FF L @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.3744 vs 0.1768 placebo L @ 24wk62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
Rescue Puffs -0.2 vs 0.6 FF Puffs @ 4wk100/250 µg
absolute change · Puffs
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
0 vs 0.6 FF Puffs @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-0.4 vs 0.6 FF Puffs @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-0.5 vs 0.6 FF Puffs @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
E-RS Total -1.5 vs 0.5 FF score @ 4wk100/250 µg
absolute change · score
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
-1.5 vs 0.5 FF score @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-2.6 vs 0.5 FF score @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-2.5 vs 0.5 FF score @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Morning PEF 10.5 vs -14.2 FF L/min @ 4wk100/250 µg
absolute change · L/min
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
5.5 vs -14.2 FF L/min @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
3.9 vs -14.2 FF L/min @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
7.6 vs -14.2 FF L/min @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ipratropium's landscape · Umeclidinium's landscape